Abstract
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Current Cardiology Reviews
Title:Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volume: 7 Issue: 4
Author(s): Maria Volkova and Raymond Russell
Affiliation:
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Abstract: Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Export Options
About this article
Cite this article as:
Volkova Maria and Russell Raymond, Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment, Current Cardiology Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157340311799960645
DOI https://dx.doi.org/10.2174/157340311799960645 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology The Chaperone-like Activity of Rat HspB8/Hsp22 and Dynamic Molecular Transition Related to Oligomeric Architectures In Vitro
Protein & Peptide Letters Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Current Molecular Medicine Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Exercise-induced Physiological Hypertrophy: Insights from Genomics
Current Genomics Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Pathological Roles of Iron in Cardiovascular Disease
Current Drug Targets Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics